Literature DB >> 15347724

Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET.

Jian-Qiang Lu1, Masanori Ichise, Jeih-San Liow, Subroto Ghose, Doug Vines, Robert B Innis.   

Abstract

UNLABELLED: 11C-Labeled 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (DASB) is a selective radioligand for the in vivo quantitation of serotonin transporters (SERTs) using PET. The goal of this study was to provide dosimetry estimates for 11C-DASB based on human whole-body PET.
METHODS: Dynamic whole-body PET scans were acquired for 7 subjects after the injection of 669 +/- 97 MBq (18.1 +/- 2.6 mCi) of 11C-DASB. The acquisition for each subject was obtained at 14 time points for a total of 115 min after injection of the radioligand. Regions of interest were placed over compressed planar images of source organs that could be visually identified to generate time-activity curves. Radiation burden to the body was calculated from residence times of these source organs using the MIRDOSE3.1 program.
RESULTS: The organs with high radiation burden included the lungs, urinary bladder wall, kidneys, gallbladder wall, heart wall, spleen, and liver. The activity peaked within 10 min after the injection of 11C-DASB for all these organs except two--the excretory organs gallbladder and urinary bladder wall, which had peak activities at 32 and 22 min, respectively. Monoexponential fitting of activity overlying the urinary bladder suggested that approximately 12% of activity was excreted via the urine. Simulations in which the urinary voiding interval was decreased from 4.8 to 0.6 h produced only modest effects on the dose to the urinary bladder wall. With a 2.4-h voiding interval, the calculated effective dose was 6.98 microGy/MBq (25.8 mrem/mCi).
CONCLUSION: The estimated radiation burden of 11C-DASB is relatively modest and would allow multiple PET examinations of the same research subject per year.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347724

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies.

Authors:  Paolo Zanotti-Fregonara; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

2.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

3.  Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.

Authors:  Akihiro Takano; Christer Halldin; Andrea Varrone; Per Karlsson; Nils Sjöholm; James B Stubbs; Magnus Schou; Anu J Airaksinen; Johannes Tauscher; Balázs Gulyás
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-14       Impact factor: 9.236

4.  Impact of Region-of-Interest Delineation Methods, Reconstruction Algorithms, and Intra- and Inter-Operator Variability on Internal Dosimetry Estimates Using PET.

Authors:  N López-Vilanova; J Pavía; M A Duch; A Catafau; D Ros; S Bullich
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

5.  Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

Authors:  Santiago Bullich; Mark Slifstein; Jan Passchier; N Venkatesha Murthy; Lawrence S Kegeles; Jong-Hoon Kim; Xiaoyan Xu; Roger N Gunn; Raul Herance; Juan Domingo Gispert; Antonio Gutiérrez; Magí Farré; Marc Laruelle; Ana M Catafau
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

6.  Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation.

Authors:  Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

7.  Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Authors:  Ya-Yao Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Hanna Ng; Jon C Mirsalis; Ying-Kai Fu; Tieh-Chi Chu; Wen-Sheng Huang; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

8.  Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data.

Authors:  Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

9.  Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET.

Authors:  Hans Herzog; David Elmenhorst; Oliver Winz; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

10.  Toxicity and radiation dosimetry studies of the serotonin transporter radioligand [(18) F]AFM in rats and monkeys.

Authors:  Ya-Yao Huang; Chen-Yi Cheng; Wen-Sheng Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Yiyun Huang; Chyng-Yann Shiue
Journal:  EJNMMI Res       Date:  2014-12-29       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.